Livzon Pharmaceutical Group Inc. (HKG:1513)

Market Cap	32.68B
Revenue (ttm)	12.95B
Net Income (ttm)	2.34B
Shares Out	n/a
EPS (ttm)	2.61
PE Ratio	13.96
Forward PE	13.39
Dividend	1.20 (3.83%)
Ex-Dividend Date	Jun 13, 2025

Volume	324,150
Average Volume	883,585
Open	30.86
Previous Close	31.28
Day's Range	30.58 - 31.08
52-Week Range	24.85 - 41.85
Beta	0.32
RSI	39.95
Earnings Date	Oct 24, 2025

About HKG:1513

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People’s Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1985
• Employees: 9,067
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1513

Financial Performance

In 2024, HKG:1513's revenue was 11.81 billion, a decrease of -4.97% compared to the previous year's 12.43 billion. Earnings were 2.06 billion, an increase of 5.50%.

Financial numbers in CNY